Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of April 2018, with the report dated April 27, 2018. The filing announces a key executive appointment within the company's leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and compensation details.
Material Changes
On April 24, 2018, the Board of Directors appointed Oz Adler as the Company's Chief Financial Officer (CFO). Mr. Adler previously served as VP Finance (March 2017–April 2018) and Controller (September 2017–April 2018). Prior to joining the company, he worked as a certified public accountant at Kost Forer Gabbay & Kasierer (Ernst & Young Global) from 2012 to September 2017.
Management Commentary and Compensation
In connection with his promotion to CFO, Mr. Adler's annual salary was increased from approximately $103,000 to approximately $120,000 under his existing employment agreement. The filing contains no guidance, outlook, or discussion of risks and contingencies beyond the personnel update.
Investor Verification Points
- Verify the effective date of Oz Adler's appointment as CFO (April 24, 2018).
- Confirm the updated annual salary of $120,000 for the CFO position.
- Note that this filing contains no financial performance data for the period.